Lakefront Biotherapeutics American Depositary Shares
LKFT
108 hedge funds and large institutions have $501M invested in Lakefront Biotherapeutics American Depositary Shares in 2021 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 37 increasing their positions, 42 reducing their positions, and 35 closing their positions.
1.32% more ownership
Funds ownership: 9.78% → 11.1% (+1.3%)
2% more capital invested
Capital invested by funds: $494M → $501M (+$7.63M)
12% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 42
18% less funds holding
Funds holding: 132 → 108 (-24)
25% less call options, than puts
Call options by funds: $27.9M | Put options by funds: $37.4M
63% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 35
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$50.1M |
| 2 |
BlackRock
New York
|
+$26.4M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$18.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$12.3M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$5.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$14.8M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$12.7M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$7.88M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.93M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$4.85M |
LKFT Hedge Fund Activity: Q2 2021 in Review
108 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q2 2021, worth a combined $501M — up 1.5% from $494M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of LKFT and 13 opened new positions — a net loss of 22 holders — while 42 trimmed existing stakes and 37 added.
The largest buyer was Deerfield Management, opening a new position worth an estimated $50.1M. The largest seller was Goldman Sachs, cutting an estimated $14.8M.
- 108 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q2 2021, down from 132 in Q1 2021.
- Funds reported $501M of Lakefront Biotherapeutics American Depositary Shares stock for Q2 2021, up 1.5% quarter-over-quarter.
- 13 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q2 2021 and 35 closed out, a net change of -22 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q2 2021 was Deerfield Management, an estimated $50.1M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q2 2021 was Goldman Sachs, an estimated $14.8M sold.
Based on aggregated 13F filings for Q2 2021.